The review, led by Tang R, Zhu M, Wu Y, Wang S and Song M, maps abnormalities across the three major branches of purine metabolism: de novo synthesis, the salvage pathway and purine catabolism. Under normal conditions, cells balance these routes according to their energy state, nutrient availability and demand for nucleotides. Cancer cells disrupt that balance. They increase the production of purine intermediates when rapid DNA replication requires a constant supply of nucleotides, while also altering recycling and degradation pathways to preserve energy and maintain signaling molecules. This reprogramming can help malignant cells survive oxygen deprivation, nutrient scarcity and treatment-induced stress—conditions that would damage or eliminate many normal cells.

The de novo pathway constructs purine nucleotides from small precursor molecules, including amino acids, bicarbonate and one-carbon units contributed through folate metabolism. Its central steps assemble an activated ribose scaffold into inosine monophosphate, or IMP, which is then converted into adenosine monophosphate and guanosine monophosphate. The review emphasizes that enzymes involved in this process can become metabolic control points in cancer. Phosphoribosyl pyrophosphate synthetase, known as PRPS, generates the activated ribose substrate required to initiate purine construction. When PRPS activity or expression rises, tumor cells may gain an expanded capacity to produce nucleotides. Other enzymes can similarly regulate the balance between nucleotide abundance, redox status and biosynthetic demand, linking the pathway directly to the ability of a cancer cell to divide.

A second important target is inosine monophosphate dehydrogenase, or IMPDH, which controls the conversion of IMP toward guanosine nucleotide production. Guanosine triphosphate is essential for RNA synthesis, protein translation, cytoskeletal organization and signaling through GTP-binding proteins. Increased IMPDH activity has been associated with the high biosynthetic demands of several cancers, making it an attractive pharmacological target. Inhibiting this enzyme can reduce guanine nucleotide availability and potentially slow proliferation, but the therapeutic effect depends on the metabolic flexibility of both tumor and normal tissues. Some cells can compensate by increasing salvage activity or importing nutrients from their surroundings, illustrating why the review presents purine metabolism as an interconnected network rather than a collection of isolated enzymes.

The salvage pathway provides that flexibility by recovering purine bases and nucleosides released during nucleic acid breakdown. Instead of rebuilding purines from the beginning, cells can recycle molecules such as hypoxanthine, guanine and adenine into usable nucleotides. This route is often more energy-efficient than de novo synthesis and may become especially important in tumors exposed to metabolic stress. The balance between synthesis and salvage can differ dramatically from one cancer type to another, or even between neighboring cells within the same tumor. Such heterogeneity may explain why a drug that produces a strong response in one malignancy has limited activity in another. It also raises the possibility that combined treatment could block both new purine production and the recycling mechanisms that allow cancer cells to escape metabolic pressure.

Purine breakdown generates additional signals with consequences beyond nucleotide disposal. Adenosine deaminase, or ADA, is one of the enzymes highlighted in the review because it regulates the levels of adenosine and related metabolites. Adenosine can accumulate in the tumor microenvironment, particularly under conditions of hypoxia, tissue damage and inflammation. By binding to adenosine receptors on immune cells, it can suppress antitumor activity, reduce the function of cytotoxic lymphocytes and promote an immunosuppressive environment. Abnormal purine catabolism may therefore help tumors evade immune surveillance while simultaneously supplying metabolic advantages. The authors argue that enzymes such as ADA should be viewed as multifunctional regulators that connect intracellular metabolism with communication between cancer cells, immune cells and stromal tissue.

This connection between metabolism and the tumor microenvironment is central to the therapeutic promise of the field. A tumor is not a uniform mass of identical cells but a changing ecosystem in which malignant cells compete and cooperate with blood vessels, fibroblasts, immune populations and extracellular matrix. These components exchange metabolites and respond to one another’s demands. A drug that blocks purine synthesis inside cancer cells could cause compensatory changes in surrounding tissue, allowing tumors to obtain nucleosides or alternative nutrients. Conversely, altering extracellular adenosine levels could reshape immune behavior in ways that influence the response to immunotherapy. The review therefore supports the development of purine-targeting drugs in rational combinations, potentially alongside chemotherapy, targeted agents, immune checkpoint inhibitors or treatments that interfere with nutrient transport.

Several compounds that affect purine metabolism already demonstrate the clinical relevance of this strategy. Drugs that inhibit nucleotide synthesis have long been used in cancer treatment, although their activity can be accompanied by toxicity because healthy tissues with rapid turnover also require purines. The next generation of therapies will need to exploit differences between malignant and normal cells, such as oncogene-driven enzyme overexpression, unusual dependence on a salvage route or an inability to adapt when one metabolic branch is blocked. Selective inhibitors directed at PRPS, IMPDH, ADA and other network components could provide greater precision, but the review cautions that enzyme inhibition alone may not be sufficient. Tumors can activate parallel pathways, alter substrate uptake or select resistant populations, making dose, timing and combination design decisive factors.

Future progress will depend on measuring purine metabolism at the level of individual cells and spatially defined tumor regions. Conventional bulk analysis can conceal major differences between cancer cells located near blood vessels, oxygen-poor cores or immune-rich boundaries. Single-cell sequencing may reveal which enzymes are active in distinct malignant and immune populations, while spatial multi-omics can show where metabolic interactions occur within the tumor architecture. Integrating gene expression with metabolite measurements, protein activity and treatment response could identify patients whose tumors are genuinely dependent on a particular purine pathway. Such precision approaches may also help predict toxicity and reveal when metabolic inhibitors should be paired with immunotherapy or other treatments.

The review presents purine metabolism as more than a consequence of rapid cancer growth. It is described as a strategic vulnerability that can influence proliferation, survival, immune suppression and resistance to therapy at the same time. Yet the authors stress that successful translation will require a detailed understanding of metabolic heterogeneity and adaptation. By defining the regulatory networks that control purine production, recycling and degradation, researchers may be able to move beyond broadly toxic antimetabolites toward selective treatments that attack the unique biochemical dependencies of individual tumors. The emerging goal is not simply to deprive cancer cells of nucleotides, but to disrupt the metabolic circuitry that allows them to grow, communicate and withstand treatment.

Subject of Research: Purine metabolism and its role in cancer progression, immune microenvironment remodeling and therapy resistance.

Article Title: Targeting purine metabolism as the next generation of cancer therapeutic strategies

News Publication Date: 14-Aug-2026

Web References: https://doi.org/10.55092/acr20260010

References: Tang R, Zhu M, Wu Y, Wang S, Song M. “Targeting purine metabolism as the next generation of cancer therapeutic strategies.” Advanced Cancer Research, 2026(2):0010. DOI: 10.55092/acr20260010.

Image Credits: Mengqiu Song/Zhengzhou University, China

Keywords: cancer metabolism, purine metabolism, PRPS, IMPDH, ADA, nucleotide synthesis, salvage pathway, purine catabolism, tumor microenvironment, immunotherapy, metabolic reprogramming, cancer therapy resistance

Succinate dehydrogenase, a well-characterized enzyme complex serving dual roles in the tricarboxylic acid (TCA) cycle and the mitochondrial respiratory chain, has long been a subject of intense interest. Its loss or mutation has been implicated in various cancers, especially those associated with hereditary paragangliomas and pheochromocytomas. The current study, however, shifts focus onto the biochemical consequences arising from SDH loss that extend beyond mitochondrial dysfunction, illuminating its influence on nucleotide biosynthesis—a cornerstone for cellular proliferation.

The research team demonstrated that depletion of SDH leads to an intracellular accumulation of succinate. While succinate’s role as an oncometabolite, capable of modulating epigenetic landscapes through competitive inhibition of α-ketoglutarate-dependent dioxygenases, is well documented, this investigation highlights a distinct metabolic function. Succinate was found to directly inhibit ATCase, an enzyme catalyzing the condensation of carbamoyl phosphate and aspartate into carbamoyl aspartate, a pivotal step in the pyrimidine synthesis pathway.

Pyrimidine nucleotides, vital for DNA and RNA synthesis, must be tightly regulated to meet cellular demands, especially in rapidly dividing cells such as tumors. By impairing ATCase activity, succinate accumulation effectively throttles the supply of pyrimidine precursors, thereby exerting a suppressive effect on nucleotide biosynthesis. This metabolite-enzyme interaction reveals a previously underappreciated metabolic checkpoint governed by mitochondrial signal states.

Methodologically, the researchers employed a combination of genetic knockdown models, metabolomic profiling, and enzymatic assays to dissect the cascade triggered by SDH loss. These approaches illuminated not only the increase in succinate levels but also the subsequent restoration of pyrimidine biosynthesis upon pharmacological or genetic attenuation of succinate’s inhibitory effect on ATCase. This feedback loop provides compelling evidence for a metabolic nexus connecting mitochondrial dysfunction and nucleotide metabolism.

The implications of these findings extend into the realm of oncology, where metabolic reprogramming is a hallmark of cancer progression. The suppression of pyrimidine biosynthesis via succinate-mediated ATCase inhibition may contribute to replication stress or DNA damage responses, thereby influencing tumor cell survival and proliferation. Intriguingly, this mechanism could also explain the paradoxical growth arrest observed in some SDH-deficient tumors, challenging prevailing models that attribute oncogenicity solely to metabolic hyperactivation.

Furthermore, this work prompts reconsideration of therapeutics targeting metabolic enzymes. Drugs that modulate succinate levels, or directly influence the activity of ATCase, could potentiate antineoplastic strategies by exploiting the vulnerabilities uncovered in SDH-deficient metabolic contexts. It also suggests that metabolic profiling of succinate and pyrimidine intermediates might serve as biomarkers for tumor classification or treatment response monitoring.

Beyond oncology, the study sheds light on fundamental cellular physiology. The dual functionality of SDH as a metabolic switch underlines how mitochondrial perturbations have far-reaching effects beyond energy homeostasis. By delineating the biochemical crosstalk between the TCA cycle and nucleotide synthesis, the authors chart new conceptual territory in metabolic regulation, hinting at similar mechanisms that might operate in diverse physiological or pathological settings.

Significantly, the research underscores the importance of enzyme-substrate interactions in metabolic control. The allosteric inhibition of ATCase by succinate exemplifies how metabolite accumulation can serve both as a signaling molecule and a direct regulator of enzymatic pathways. This paradigm inspires deeper interrogation into other metabolite-enzyme pairs that may govern cellular states in health and disease.

The study also raises provocative questions regarding metabolic compensation and adaptation. How cells negotiate the buildup of succinate and the concomitant suppression of pyrimidine synthesis could determine their fate under stress or oncogenic transformation. Future research may focus on unraveling adaptive responses that override or circumvent these metabolic blocks, potentially revealing novel drug targets or resistance mechanisms.

Moreover, the authors highlight the technical sophistication of their approach, combining high-resolution metabolomics with structural and kinetic analyses. Such integrative strategies are critical for unraveling complex metabolic interdependencies, moving beyond simple correlations to mechanistic clarity. This investigative rigor enhances confidence in the biological significance of the findings and sets a new standard for metabolic research.

In summary, this pioneering work redefines the metabolic landscape associated with SDH loss by uncovering a functional link between mitochondrial dysfunction and nucleotide synthesis inhibition. The discovery that succinate directly impedes ATCase activity to suppress pyrimidine biosynthesis not only enriches our comprehension of cellular metabolism but also holds transformative potential for therapeutic innovation in cancer and beyond. As the scientific community digests these insights, new paradigms for targeting metabolic vulnerabilities are poised to emerge.

The study exemplifies the power of integrative metabolic research to reveal unexpected regulatory circuits within the cell. By melding biochemical, genetic, and metabolic data, the investigators have elucidated a nuanced mechanism through which a classic mitochondrial enzyme influences fundamental anabolic pathways. This work will undoubtedly catalyze further investigations into metabolite-driven regulation and its implications for disease.

Looking forward, the research invites exploration into the broader landscape of TCA cycle metabolites as modulators of enzymatic networks. Understanding how other metabolites might exert similar regulatory roles could recalibrate current models of metabolic control and inspire novel therapeutic approaches for metabolic diseases and cancer.

This research not only advances our grasp of cellular metabolism but also underscores the intricate connectivity between mitochondrial function and biosynthetic pathways essential for cell proliferation. The identification of succinate as a potent inhibitor of pyrimidine biosynthesis via ATCase reveals a compelling metabolic checkpoint that may be exploited to selectively target SDH-deficient tumors.

In conclusion, the revelation that SDH loss leads to succinate accumulation which in turn suppresses pyrimidine biosynthesis through the inhibition of ATCase marks a significant leap in cancer metabolism research. These findings illuminate a complex interplay of metabolic pathways that could reshape therapeutic strategies, offering hope for more effective treatments by harnessing metabolic vulnerabilities inherent in tumor biology.

Subject of Research: Metabolic regulation of pyrimidine biosynthesis following succinate dehydrogenase loss

Article Title: Succinate dehydrogenase loss suppresses pyrimidine biosynthesis via succinate-mediated inhibition of aspartate transcarbamylase

Article References:
Hart, M.L., Sokolov, D., Danquah, S. et al. Succinate dehydrogenase loss suppresses pyrimidine biosynthesis via succinate-mediated inhibition of aspartate transcarbamylase. Nat Metab (2026). https://doi.org/10.1038/s42255-026-01524-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s42255-026-01524-w